Search tips
Search criteria 


Logo of jcoHomeThis ArticleSearchSubmitASCO JCO Homepage
J Clin Oncol. 2009 October 10; 27(29): 4839–4847.
Published online 2009 August 31. doi:  10.1200/JCO.2009.22.3271
PMCID: PMC2764392

Assessing Risk of Venous Thromboembolism in the Patient With Cancer



Patients with cancer are increasingly at risk for venous thromboembolism (VTE). Rates of VTE, however, vary markedly among patients with cancer.


This review focuses on recent data derived from population-based, hospital-based, and outpatient cohort studies of patients with cancer that have identified multiple clinical risk factors as well as candidate laboratory biomarkers predictive of VTE.


Clinical risk factors for cancer-associated VTE include primary tumor site, stage, initial period after diagnosis, presence and number of comorbidities, and treatment modalities including systemic chemotherapy, antiangiogenic therapy, and hospitalization. Candidate predictive biomarkers include elevated platelet or leukocyte counts, tissue factor, soluble P-selectin, and D-dimer. A recently validated risk model, incorporating some of these factors, can help differentiate patients at high or low risk for developing VTE while receiving chemotherapy.


Identifying patients with cancer who are most at risk for VTE is essential to better target thromboprophylaxis, with the eventual goal of reducing the burden as well as the consequences of VTE for patients with cancer.


The risk of venous thromboembolism (VTE), although considerably elevated in patients with cancer, varies markedly between patients and even within the same patient at different time points during the course of malignancy. A growing body of literature from a variety of sources, including population-based studies,1 hospital discharge databases,2,3 cancer registries,4 retrospective cohorts,5 and prospective observational studies,69 has led to an increased understanding of the clinical factors affecting risk of VTE. Exploratory studies have also identified candidate biomarkers predictive of VTE in patients with cancer.7,10,11 This review will discuss the findings and limitations of data, describing known clinical risk factors, candidate laboratory biomarkers, and a recently validated risk model that can help identify patients with cancer most at risk for VTE.


It is difficult to directly compare reported rates of VTE in patients with cancer because the studies vary with regard to patient population, duration of follow-up, period of study, and method of detecting and reporting VTE. This is evident when comparing rates of VTE in large studies of pooled patients with cancer (Table 1). The highest rates of VTE are reported in cohorts consisting of hospitalized neutropenic patients with cancer (6.4%)13 and patients admitted to an inpatient oncology service (7.8%).5 Both clinical situations suggest active treatment, which in turn is a well-known risk factor for cancer-associated VTE. In contrast, rates of VTE are lower (0.6% to 3.2%) in study populations from databases with a likely higher proportion of patients who carry a remote diagnosis of cancer.3,4,12 The frequency of VTE has also increased over time, and rates are therefore higher in more recent studies.24 Further confusion is added by the fact that VTE rates may be significantly underestimated when relying on toxicity data from clinical trials. In a prospective randomized study of patients with advanced colorectal cancer, VTE was initially reported as a toxicity during treatment in only two of 266 patients (0.8%); a subsequent retrospective review of the same population found VTE in an additional 25 patients, for an actual VTE rate of 10.2%.16 Despite these complexities, there is broad agreement in the literature regarding most risk factors for cancer-associated VTE. A comprehensive list of clinical risk factors and candidate biomarkers is provided in Table 2.

Table 1.
Reported Incidence of VTE in Large Studies of Pooled Patients With Cancer
Table 2.
Clinical Risk Factors and Candidate Biomarkers for Cancer-Associated VTE


Type of Cancer

The primary site of cancer is consistently identified as a risk factor for VTE across a variety of studies. Although specific incidence rates may vary based on the clinical setting, patients with cancers of the pancreas, stomach, uterus, kidney, lung, and primary brain tumors are associated with the highest rates of VTE (Table 3). More recent studies have identified a high risk of VTE in association with hematologic malignancies as well (Appendix Table A1, online only). In a population-based case-control study, patients with hematologic malignancies in fact had the highest risk of VTE (odds ratio [OR] = 28.0; 95% CI, 4.0 to 199.7), followed by lung (OR = 22.2; 95% CI, 3.6 to 136.1) and gastrointestinal cancers (OR = 20.3; 95% CI, 4.9 to 83.0).1 Rates can vary quite markedly between cancer types. In an analysis of the California Cancer Registry, rates of VTE were 20% and 10.7% among patients with advanced pancreas and stomach cancers, respectively, but only 0.9% and 2.8% in patients with advanced prostate and breast cancers, respectively.4 VTE rates can also vary by histologic subtype. In patients with non–small-cell lung cancer, rates are higher in patients with adenocarcinoma compared with those with squamous cell carcinoma (hazard ratios [HRs] ranging from 1.9 to 3.1).20,21

Table 3.
Incidence of VTE in Specific Solid Tumors

It should be noted that highly prevalent cancers with lower rates of VTE can contribute significantly to the overall burden of VTE. For instance, in a study of hospitalized patients, more than one third of VTE events occurred in patients with non-Hodgkin's lymphoma and leukemia, even though the highest rates were observed in patients with pancreatic and gastric cancers.16

Stage of Cancer

Large cohort studies have identified stage as a major risk factor for VTE.5,4 In oncologic surgery patients, advanced stage is also associated with increased risk of VTE (OR = 2.7; 95% CI, 1.4 to 5.2).6 It is possible, however, that in large study populations, advanced stage may be a surrogate for poor performance status. Among ambulatory patients with cancer with good performance status receiving chemotherapy, stage was in fact not a predictor of VTE.8 Studies in outpatients with ovarian cancer also did not identify an association between stage and VTE.76,77

Initial Period After Diagnosis

The risk of VTE is highest in the immediate period after diagnosis of cancer. In a population-based study, the adjusted OR for developing VTE in the first 3 months was 53.5 (95% CI, 8.6 to 334.3), declining to 14.3 (95% CI, 5.8 to 35.2) and 3.6 (95% CI, 2.0 to 6.5) in the 3 month to 1 year and 1 to 3 year intervals, respectively.1 Indeed, it took 15 years after diagnosis before the risk subsided to levels observed in the general population. Many therapeutic interventions occur in this initial period, which likely contribute to risk. However, even in patients receiving a single treatment modality such as chemotherapy, the risk is highest in the initial period of treatment. For instance, among patients with diffuse large B-cell lymphoma, 82% of VTE events occurred during the first three cycles of chemotherapy.17 Similarly, in patients with transitional-cell carcinoma and lung cancer undergoing chemotherapy, 77% and 45% of vascular events, respectively, occurred during the first two cycles of therapy.18,19


Systemic Therapy

Chemotherapy is associated with a two- to six-fold increased risk of VTE compared with the general population.14,22 Rates of VTE seem to be increasing, particularly in association with chemotherapy. Among hospitalized patients receiving chemotherapy, the rates of VTE increased from 3.9% to 5.7% per admission from 1995 to 2003, an increase of 47%.2 Specific chemotherapeutic agents may be associated with higher rates of VTE. In a prospective study, platinum-based regimens were significantly associated with VTE (P = .03).9 Even within this class of agents, rates may be higher in patients receiving cisplatin as compared with oxaliplatin.87 Altering the schedule of chemotherapy, such as by using an intermittent regimen, may reduce the risk of VTE.16

Thalidomide has been associated with high rates of VTE, ranging from 12% to 28%, when given in combination with dexamethasone or chemotherapy.2426 Regimens containing doxorubicin (OR = 4.3), newly diagnosed disease (OR = 2.5) and presence of chromosome 11 abnormality (OR = 1.8) are predictors of thalidomide-associated VTE.32 Lenalidomide is also associated with high rates of VTE, ranging from 5% to 75%.2729 Bevacizumab-containing regimens were associated with increased risk for arterial events (HR = 2.0; 95% CI, 1.1 to 3.8) but not for VTE (HR = 0.9; 95% CI, 0.7 to 1.2) in an initial individual patient data meta-analysis of randomized clinical trials.31 However, a larger aggregate data meta-analysis found that patients with cancer receiving bevacizumab had a significantly increased risk of VTE (relative risk, 1.3; 95% CI, 1.1 to 1.6) as well.88 High rates of both venous and arterial events have been observed in clinical trials of other antiangiogenic agents as well,30 and this toxicity may therefore be a class effect.

Supportive Therapy

Patients with cancer often receive erythropoiesis-stimulating agents (ESAs) for the treatment of anemia. In a systematic review of randomized controlled trials, 229 of the 3,728 patients treated with darbepoetin or epoetin had thromboembolic events as compared with 118 events in 3,041 untreated controls (relative risk = 1.7; 95% CI, 1.4 to 2.1).33 Although transfusions are being advocated as an alternative to ESAs for the treatment of anemia, a recent retrospective analysis of hospitalized patients with cancer found RBC transfusions were independently associated with an increased risk of VTE (OR = 1.6; 95% CI, 1.5 to 1.7), arterial events (OR = 1.5; 95% CI, 1.5 to 1.6), and in-hospital mortality.34 Platelet transfusions were also noted to have a similar association. The evidence supporting an association of myeloid growth factors with VTE is inconclusive.89


Surgery and the extended postoperative period are historically well-known high-risk settings for VTE. It should be noted, however, that in recent reports, surgery has not been found to be a major risk factor for VTE, relative to other factors.14,40,41 Rates of VTE in association with major oncologic surgical procedures have also remained relatively stable, in contrast to sharp increases observed in patients receiving chemotherapy.2 These findings are likely related to higher rates of compliance with thromboprophylaxis in the surgical setting90 and should not be interpreted to mean that oncologic surgical interventions are no longer associated with VTE. In a recent study of cancer surgical patients, risk factors for postoperative VTE included age more than 60 years (OR = 2.6; 95% CI, 1.2 to 5.7), previous VTE (OR = 6.0; 95% CI, 2.1 to 16.8), advanced cancer (OR = 2.7; 95% CI, 1.4 to 5.2), anesthesia lasting more than 2 hours (OR = 4.5; 95% CI, 1.1 to 19), and bed rest longer than 3 days (OR = 4.4; 95% CI, 2.5 to 7.8).6 Of note, 40% of VTE events occurred more than 21 days after surgery.


Hospitalization substantially increases the risk of VTE in patients with cancer (OR = 2.3; 95% CI, 1.6 to 3.4).9 The risk of VTE in a recent US study was 4.1% per hospitalization, but the risk varies widely and can be as high as 12% to 18% in specific subgroups.2,13 In an analysis of more than 1 million hospitalized US patients between 1995 and 2003, the rate of VTE increased by 28%, secondary to a near-doubling of pulmonary embolism rates from 0.8% to 1.5% (P < .0001).2

Central Venous Catheters

Indwelling vascular access devices such as central venous catheters (CVCs) are widely used in patients with cancer for infusing chemotherapy. The incidence of symptomatic catheter-related deep venous thrombosis (DVT) in adult patients ranges from 0.3% to 28%, whereas the rate of catheter-related DVT assessed by venography is 27% to 66%.38 Rates seem to be lower in more recent studies. In a recent prospective study of more than 400 patients with cancer with CVCs, 4.3% developed symptomatic CVC-related DVT.35 Risk factors associated with CVC-related DVT include more than one insertion attempt (OR = 5.5; 95% CI, 1.2 to 24.6), previous CVC insertion (OR = 3.8; 95% CI, 1.4 to 10.4), left-sided placement (OR = 3.5; 95% CI, 1.6 to 7.5), catheter tip position in the superior vena cava as compared with right atrium (OR = 2.7; 95% CI, 1.1 to 6.6), and arm ports as compared with chest ports (OR = 8.1; 95% CI, 3.5 to 19.1).35,36 The particular antineoplastic agent infused through the port may additionally influence the risk of catheter-associated DVT.37


Radiation therapy does not seem to be associated with a risk for VTE, although this has only been evaluated in a small number of studies.14,91


Comorbid Conditions

The presence and number of comorbidities influence the risk of VTE. Among hospitalized patients, comorbidities most strongly associated with VTE include infection (OR = 1.8), arterial thromboembolism (OR = 1.5), renal disease (OR = 1.5), pulmonary disease (OR = 1.4), and anemia (OR = 1.4).2 Anemia (OR = 2.4) and obesity (OR = 2.5) are associated with the risk of VTE in ambulatory patients with cancer as well.9,15 In patients with ovarian cancer, HRs for the development of VTE increase from 2.1 in patients with one comorbidity to 3.9 in patients with three comorbidities.41 This increase in risk with increasing number of comorbid conditions has been documented for patients with lung, breast, and colorectal cancer as well.21,40,65

Prior Thromboses

A past history of thrombotic events is a risk factor for developing VTE. In a study of patients with cancer undergoing surgery, those with previous VTE had a significantly higher risk of developing new thrombosis (OR = 6.0; 95% CI, 2.1 to 16.8).6 Prior VTE has also been demonstrated to be a risk factor for VTE in patients with ovarian and prostate cancers and myeloma.4547 Local thromboses may predispose to systemic events as well. In a retrospective study of patients with hepatocellular carcinoma, there was a 2.6-fold increase in VTE in patients with concurrent portal vein thrombosis compared with those without.48 Finally, arterial thrombotic events are associated with venous events (OR = 1.5; 95% CI, 1.4 to 1.5).2

Prothrombotic Mutations

A population-based case-control study estimated that patients with cancer and factor V Leiden had an increased risk of VTE compared with patients with cancer without the mutation (OR = 2.2; 95% CI, 0.3 to 17.8).1 Other studies have shown similar increased risk with presence of factor V Leiden mutation (OR, 0.6 to 1.7).43,44,92 Similarly, patients with cancer with prothrombin gene mutation also have an increased risk of VTE (OR, 1.2 to 6.7).43,44 In a recent meta-analysis, the estimated attributable risk of CVC-related thrombosis was 13.1% for factor V Leiden and 4.5% for prothrombin gene mutation.93 A family history of VTE, which may be a surrogate for inherited thrombophilia, has also been associated with VTE.9

Age, Sex, and Race

In hospitalized patients with cancer, older age (≥ 65 years) is associated with a slightly elevated risk of VTE (OR = 1.1; 95% CI, 1.0 to 1.1).2 Similarly, in the surgical setting, VTE occurred more frequently in patients older than 60 years of age (OR = 2.6; 95% CI, 1.2 to 5.7).6 However, in the ambulatory setting, age was not a significant risk factor when the study population overwhelmingly comprised patients with a good performance status.8

Many studies have shown no significant sex difference in VTE rates.4,5,8,21,40 However, a study of hospitalized patients reported an overall increased risk of VTE in women (OR = 1.1; 95% CI, 1.1 to 1.2).2 Some studies have demonstrated an association between race and risk of VTE in cancer. Rates of VTE seem to be higher in African American patients (OR = 1.2; 95% CI, 1.2 to 1.2) and lower in Asians/Pacific Islanders (OR = 0.7; 95% CI, 0.7 to 0.8).2 Some of these differences may be related to the type of cancer. In an analysis of the California Cancer Registry, African Americans with uterine cancer were more likely to develop VTE, but those with lung cancer and lymphoma were less likely to develop VTE.4

Performance Status and Mobility

Immobility, which leads to venous stasis, has long been recognized as a risk factor for VTE. In patients with cancer, performance status is a widely used clinical assessment tool used to assess mobility. In a prospective study, 31% of patients with lung cancer with poor performance status on chemotherapy had VTE, compared with 15% with better performance status.19 In a large study of cancer outpatients, there was a nonsignificant trend toward higher rates of VTE in patients with poor performance status, but more than 90% of patients had an excellent performance status.8 Poor performance status has also been associated with higher rates of recurrent VTE in patients with cancer.49 In surgical patients with cancer, those on bed rest for a period longer than 3 days had significantly higher rates of VTE (OR = 4.4; 95% CI, 2.5 to 7.8).6


Promising initial and exploratory studies have identified laboratory biomarkers—ranging from tests as simple as components of the complete blood count to a variety of novel assays—that may be predictive of VTE in cancer (Table 2).

Platelet and Leukocyte Counts

In an initial analysis of data from a prospective observational study of patients initiating chemotherapy, elevated prechemotherapy platelet counts were strongly associated with VTE.8 VTE occurred in nearly 4% over 2.5 months for patients with a prechemotherapy platelet count ≥ 350,000/μL, significantly higher than the rate of 1.25% for patients with prechemotherapy platelet count of less than 200,000/μL (P for trend = .0003). Additionally, patients who developed VTE had significantly elevated mean platelet counts before each cycle of chemotherapy when compared with patients who did not develop VTE (P = .001). In an expanded analysis of this registry, a prechemotherapy leukocyte count more than 11,000/μL was also found to be significantly and independently associated with an increased risk of subsequent VTE.15 In multivariate analysis, both elevated baseline platelet (OR = 1.8; 95% CI, 1.1 to 3.2) and leukocyte (OR = 2.2; 95% CI, 1.2 to 4.0) counts were independently associated with VTE. Additional reports seem to confirm these findings.39,5052,87

Tissue Factor

Tissue factor (TF) is the physiologic initiator of coagulation. TF is commonly expressed in a variety of malignancies, and researchers are increasingly focused on its role in the pathophysiology of cancer-associated thrombosis.11,94 TF can be evaluated in a variety of ways, including by studying the degree of TF expression in tumor cells by immunohistochemistry,53,95 measuring systemic TF antigen levels,10,96 or TF activity.10,11 In a small, retrospective study, patients with pancreatic cancer with high TF expression in resected tumor specimens had a subsequent VTE rate of 26.3% compared with 4.5% in patients with low TF expression (P = .04).53 Similar data have been reported in ovarian cancer as well.70 In another small pilot study of patients with pancreatic cancer, elevated levels of systemic TF, measured either in terms of antigen or activity levels, were predictive of VTE.10 Of note, in patients with ovarian cancer, preoperative TF levels were associated with worsened mortality.96 Several ongoing studies are studying the utility of TF as a biomarker for cancer-associated VTE. It remains to be seen whether this approach can be generalized to all patients with cancer or will only be useful in specific cancer types. Investigators are also yet to agree on the most optimal assay for measuring TF.


Markers of hemostatic activation, particularly D-dimer, have been observed to be elevated in patients with cancer.55 In a prospective analysis, patients with colorectal cancer had significantly higher levels of TAT and F1 + 2 than controls with benign colorectal disease.97 Elevated postoperative levels of these hemostatic markers also predicted for development of postoperative DVT. Elevated D-dimer levels have also been shown to be predictive of recurrent VTE in patients with cancer.49 Conversely, a negative D-dimer test in the setting of low likelihood of VTE can be used to effectively rule out a diagnosis of DVT, although this combination rarely occurs in patients with cancer.98,99

C-Reactive Protein

C-reactive protein is a downstream marker of the inflammatory process and is considered a predictor of cardiovascular events and mortality. In a prospective single-institution observational study of 507 patients with cancer, an elevated C-reactive protein (> 400 mg/dL) was associated in multivariate analysis with the development of VTE.9

Soluble P-Selectin

Interactions between P-selectin and circulating carcinoma mucins have been proposed as a possible explanation for Trousseau's syndrome.100 In a prospective observational study of 687 patients with cancer with newly diagnosed or recurrent cancer, elevated plasma soluble P-selectin levels (> 53.1 ng/mL, representing the 75th percentile) were found to be predictive of VTE (HR = 2.6; 95% CI, 1.4 to 4.9; P = .003).7


The majority of patients with cancer are currently treated primarily in the outpatient setting. Multiple clinical trials of thromboprophylaxis have been conducted in ambulatory patients with cancer selected by individual risk factors, such as metastatic breast and lung cancer or presence of intravenous catheters.101105 However, results have been conflicting, with a majority of studies not showing a benefit for prophylaxis owing to low event rates (typically < 5%). To reduce the public health burden of VTE, it is important to identify patients with cancer at highest risk for VTE for whom prophylaxis may be beneficial. Conversely, a majority of patients with cancer do not develop VTE, and it is equally important to exclude such low-risk patients from studies of prophylaxis. A short-term symptomatic VTE rate of approximately 5% to 7% would be similar to or greater than that reported in hospitalized or postoperative patients for whom VTE prophylaxis has been shown to be highly effective.106108

A validated risk model for identifying patients at high risk for VTE has recently been published (Table 4).15 Risk factors for VTE were studied in a randomly selected development cohort of 2,701 ambulatory patients with cancer initiating chemotherapy. The risk model was then validated in an independent cohort of 1,365 patients from the same study. Five predictive variables present before initiation of chemotherapy were identified in a stage-adjusted multivariate model in the development cohort: primary site (type) of cancer, platelet count ≥ 350,000/μL, hemoglobin less than 10 g/dL and/or use of ESAs, leukocyte count more than 11,000/μL, and body mass index ≥ 35 kg/m2. Rates of VTE in the development and validation cohorts, respectively, were 0.8% and 0.3% in the low-risk category (score = 0), 1.8% and 2% in the intermediate-risk category (score = 1 to 2), and 7.1% and 6.7% in the high-risk category (score ≥ 3) over a median period of 2.5 months (C statistic = 0.7 for both cohorts). At the cutoff point for high risk (score ≥ 3), the model had a negative predictive value of 98.5%. Thus the model is successful in identifying a low-risk population for whom prophylaxis is unlikely to be beneficial, as well as a high-risk population for whom prophylaxis studies are necessary. One limitation of this study is that patient accrual was completed before widespread use of bevacizumab. Further, the value of the C statistic suggests that incorporating additional variables such as biomarkers may increase the robustness of this model. However, the high rate of symptomatic VTE observed in the high-risk subgroup of patients is similar to that seen in hospitalized or surgical patients for whom prophylaxis is both safe and effective.106108 A recent analysis reveals that this risk model is also highly predictive of mortality in patients with cancer.109 The National Heart, Lung, and Blood Institute has recently funded a study of thromboprophylaxis in patients deemed high-risk based on this model ( No. NCT00876915).

Table 4.
Predictive Model for Chemotherapy-Associated VTE15

In conclusion, important strides have been made in the past decade regarding our understanding of risk factors for cancer-associated thrombosis. Yet, many gaps remain in our knowledge and understanding of this devastating illness. Ongoing and future studies that further explore the role of model- and biomarker-based approaches will hopefully allow for targeting prophylaxis based on individual risk in the patient with cancer. In turn, this could lead to a reduction of the public health burden of VTE and its attendant consequences for patients with cancer.


Table A1.

Incidence of VTE in Specific Hematologic Malignancies

StudyCancerStageType of StudyYears of StudyTreatmentNo. of PatientsMedian Follow-UpIncidence (%)
Ziegler S, Sperr WR, Knobl P, et al: Thromb Res 115:59-64, 2005LeukemiaNARetrospective cohort1979-2001NA719NA2.1
De Stefano V, Sora F, Rossi E, et al: J Thromb Haemost 3:1985-1992, 2005LeukemiaNAProspective cohort1994-2003NA379NA5.0
Mohren M, Markmann I, Jentsch-Ullrich K, et al: Br J Cancer 94:200-202, 2006LeukemiaNARetrospective cohort1992-2005Chemotherapy455NA12.1
Caruso V, Iacoviello L, Di Castelnuovo A, et al: J Thromb Haemost 5:621-623, 2007LeukemiaNAMeta-analysisNAChemotherapy323NA5.9
Caruso V, Iacoviello L, Di Castelnuovo A, et al: Blood 108:2216-2222, 2006LeukemiaNAMeta-analysisNAChemotherapy1752NA5.2
Ku G: Blood 10:1182, 2008LeukemiaNARetrospective cohort1990-2000NA78762 yr5.2
Seifter EJ, Young RC, Longo DL: Cancer Treat Rep 69:1011-1013, 1985LymphomaNARetrospective cohort1985Chemotherapy177NA6
Ottinger H, Belka C, Kozole G, et al: Eur J Haematol 54:186-194, 1995LymphomaI-IVRetrospective cohort1995Chemotherapy593NA6.6
Mohren M, Markmann I, Jentsch-Ullrich K, et al: Br J Cancer 92:1349-1351, 2005LymphomaI-IVRetrospective cohort1991-2004NA1038NA7.7
Komrokji et al17LymphomaI-IVRetrospective cohort1990-2001NA211NA13.4
Goldschmidt N, Linetsky E, Shalom E, et al: Cancer 98:1239-1242, 2003Lymphoma (CNS)NARetrospective cohort1992-2001MTX-based chemotherapy44NA60
Minnema MC, Breitkreutz I, Auwerda JJ, et al: Leukemia 18:2044-2046, 2004MyelomaII-IIIProspective cohort2001-2003Chemotherapy thalidomide LMWH412NA7.2
Zangari M, Barlogie B, Anaissie E, et al: Br J Haematol 126:715-721, 2004MyelomaI-IIIProspective randomized2000-2003Chemotherapy thalidomide LMWH38612 months17.9
Srkalovic et al46MyelomaI-IVRetrospective cohort1991-2001Various404NA10
Pihusch R, Salat C, Schmidt E, et al: Transplantation 74:1303-1309, 2002TransplantNARetrospective cohort1979-1996Bone marrow transplantation447NA12.8
Gerber DE, Segal JB, Levy MY, et al: Blood 112:504-510, 2008TransplantNARetrospective cohort1993-2005Bone marrow transplantation1514180 days4.6

Abbreviations: VTE, venous thromboembolism; NA, not available; MTX, methotrexate; LMWH, low-molecular-weight heparin.


Supported by grants to A.A.K. from the National Cancer Institute (Grant No. K23 CA120587), the National Heart, Lung and Blood Institute (Grant No. 1R01HL095109-01), and the V Foundation.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None Consultant or Advisory Role: Alok A. Khorana, sanofi-aventis (C), Eisai (C), Leo Pharma (C), Pharmacyclics (C) Stock Ownership: None Honoraria: Alok A. Khorana, sanofi-aventis, Eisai Research Funding: Alok A. Khorana, Bristol-Myers Squibb, Eisai, sanofi-aventis Expert Testimony: None Other Remuneration: None


Conception and design: Alok A. Khorana

Administrative support: Alok A. Khorana

Collection and assembly of data: Gregory C. Connolly

Data analysis and interpretation: Alok A. Khorana, Gregory C. Connolly

Manuscript writing: Alok A. Khorana, Gregory C. Connolly

Final approval of manuscript: Alok A. Khorana, Gregory C. Connolly


1. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–722. [PubMed]
2. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339–2346. [PubMed]
3. Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119:60–68. [PubMed]
4. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458–464. [PubMed]
5. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost. 2002;87:575–579. [PubMed]
6. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. Ann Surg. 2006;243:89–95. [PubMed]
7. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS) Blood. 2008;112:2703–2708. [PubMed]
8. Khorana AA, Francis CW, Culakova E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104:2822–2829. [PubMed]
9. Kröger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17:297–303. [PubMed]
10. Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008;6:1983–1985. [PMC free article] [PubMed]
11. Tesselaar ME, Romijn FP, Van Der Linden IK, et al. Microparticle-associated tissue factor activity: A link between cancer and thrombosis? J Thromb Haemost. 2007;5:520–527. [PubMed]
12. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285–291. [PubMed]
13. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24:484–490. [PubMed]
14. Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: Results of a record linkage study. J Thromb Haemost. 2006;4:529–535. [PubMed]
15. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–4907. [PubMed]
16. Mandalà M. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The GISCAD alternating schedule study findings. Eur J Cancer. 2009;45:65–73. [PubMed]
17. Komrokji RS, Uppal NP, Khorana AA, et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47:1029–1033. [PubMed]
18. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160:2021–2024. [PubMed]
19. Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005;103:994–999. [PubMed]
20. Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: Higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004;2:1760–1765. [PubMed]
21. Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008;6:601–608. [PubMed]
22. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med. 2000;160:809–815. [PubMed]
23. Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer: National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996;14:2731–2737. [PubMed]
24. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89:826–831. [PubMed]
25. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344:1951–1952. [PubMed]
26. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–436. [PubMed]
27. Zonder JA, Barlogie B, Durie BG, et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: Benefit of aspirin prophylaxis. Blood. 2006;108:403. [PubMed]
28. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079–2080. [PubMed]
29. Morgan GJ, Schey SA, Wu P, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol. 2007;137:268–269. [PubMed]
30. Kuenen BC, Levi M, Meijers JC, et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol. 2003;21:2192–2198. [PubMed]
31. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–1239. [PubMed]
32. Zangari M, Barlogie B, Thertulien R, et al. Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival. Clin Lymphoma. 2003;4:32–35. [PubMed]
33. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708–714. [PubMed]
34. Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168:2377–2381. [PMC free article] [PubMed]
35. Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24:1404–1408. [PubMed]
36. Tesselaar ME, Ouwerkerk J, Nooy MA, et al. Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer. 2004;40:2253–2259. [PubMed]
37. Linenberger ML. Catheter-related thrombosis: Risks, diagnosis, and management. J Natl Compr Canc Netw. 2006;4:889–901. [PubMed]
38. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21:3665–3675. [PubMed]
39. Trujillo-Santos J, Di Micco P, Iannuzzo M, et al. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism: Findings from the RIETE Registry. Thromb Haemost. 2008;100:905–911. [PubMed]
40. Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: Incidence and effect on survival. J Clin Oncol. 2006;24:1112–1118. [PubMed]
41. Rodriguez AO, Wun T, Chew H, et al. Venous thromboembolism in ovarian cancer. Gynecol Oncol. 2007;105:784–790. [PubMed]
42. Chew HK, Wun T, Harvey D, et al. The incidence of venous thromboembolism in breast cancer patients. Breast Cancer Res Treat. 2005;94(suppl 1):S13. abstr 23.
43. Kennedy M, Andreescu AC, Greenblatt MS, et al. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol. 2005;128:386–388. [PubMed]
44. Ramacciotti E, Wolosker N, Puech-Leao P, et al. Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res. 2003;109:171–174. [PubMed]
45. Secin FP, Jiborn T, Bjartell AS, et al. Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2008;53:134–145. [PubMed]
46. Srkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004;101:558–566. [PubMed]
47. Tateo S, Mereu L, Salamano S, et al. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol. 2005;99:119–125. [PubMed]
48. Connolly GC, Chen R, Hyrien O, et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res. 2008;122:299–306. [PMC free article] [PubMed]
49. Sallah S, Husain A, Sigounas V, et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res. 2004;10:7238–7243. [PubMed]
50. Simanek R, Vormittag R, Alguel G, et al. A high platelet count independently predicts venous thromboembolism in cancer patients. J Thromb Haemost. 2007;5 abstr P-T-497.
51. Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood. 2007;109:4105. [PubMed]
52. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: Validation of a thrombosis risk score. J Thromb Haemost. 2004;2:2156–2161. [PubMed]
53. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13:2870–2875. [PubMed]
54. Uno K, Homma S, Satoh T, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007;96:290–295. [PMC free article] [PubMed]
55. Falanga A, Levine MN, Consonni R, et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial. Thromb Haemost. 1998;79:23–27. [PubMed]
56. Novotny V, Hakenberg OW, Wiessner D, et al. Perioperative complications of radical cystectomy in a contemporary series. Eur Urol. 2007;51:397–401. discussion 401-402. [PubMed]
57. Levi AD, Wallace MC, Bernstein M, et al. Venous thromboembolism after brain tumor surgery: A retrospective review. Neurosurgery. 1991;28:859–863. [PubMed]
58. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: A prospective study. Eur J Cancer. 1997;33:1592–1596. [PubMed]
59. Auguste KI, Quinones-Hinojosa A, Gadkary C, et al. Incidence of venous thromboembolism in patients undergoing craniotomy and motor mapping for glioma without intraoperative mechanical prophylaxis to the contralateral leg. J Neurosurg. 2003;99:680–684. [PubMed]
60. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106:601–608. [PubMed]
61. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404–407. [PubMed]
62. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286–294. [PubMed]
63. Clahsen PC, van de Velde CJ, Julien JP, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994;12:1266–1271. [PubMed]
64. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial: The Scottish Cancer Trials Breast Group. BMJ. 1995;311:977–980. [PMC free article] [PubMed]
65. Chew HK, Wun T, Harvey DJ, et al. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol. 2007;25:70–76. [PubMed]
66. Chen Y, Xu H, Li Y, et al. The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: A prospective analysis of 295 patients. Ann Surg Oncol. 2008;15:2847–2855. [PubMed]
67. Franchi M, Ghezzi F, Riva C, et al. Postoperative complications after pelvic lymphadenectomy for the surgical staging of endometrial cancer. J Surg Oncol. 2001;78:232–237. discussion 237-240. [PubMed]
68. Satoh T, Matsumoto K, Uno K, et al. Silent venous thromboembolism before treatment in endometrial cancer and the risk factors. Br J Cancer. 2008;99:1034–1039. [PMC free article] [PubMed]
69. Tesselaar M. Incidence of thrombosis in gastro-esophageal cancer: A cohort study of 761 patients. J Clin Oncol. 2004;22:8218.
70. Tetzlaff ED, Correa AM, Baker J, et al. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer. 2007;109:1989–1995. [PubMed]
71. Tagalakis V, Levi D, Agulnik JS, et al. High risk of deep vein thrombosis in patients with non-small cell lung cancer: A cohort study of 493 patients. J Thorac Oncol. 2007;2:729–734. [PubMed]
72. Dentali F, Malato A, Ageno W, et al. Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. J Thorac Cardiovasc Surg. 2008;135:705–706. [PubMed]
73. Arbeit JM, Lowry SF, Line BR, et al. Deep venous thromboembolism in patients undergoing inguinal lymph node dissection for melanoma. Ann Surg. 1981;194:648–655. [PubMed]
74. Krown SE, Niedzwiecki D, Hwu WJ, et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: High rate of thromboembolic events (CALGB 500102) Cancer. 2006;107:1883–1890. [PubMed]
75. Westin SN, Skinner EN, Jonsson Funk M, et al. Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer. Gynecol Oncol. 2007;105:414–417. [PubMed]
76. Satoh T, Oki A, Uno K, et al. High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer. 2007;97:1053–1057. [PMC free article] [PubMed]
77. Fotopoulou C, duBois A, Karavas AN, et al. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: An exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008;26:2683–2689. [PubMed]
78. Pinzon R, Drewinko B, Trujillo JM, et al. Pancreatic carcinoma and Trousseau's syndrome: Experience at a large cancer center. J Clin Oncol. 1986;4:509–514. [PubMed]
79. Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: A cohort study of 202 patients. Eur J Cancer. 2006;42:410–414. [PubMed]
80. Mandalà M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol. 2007;18:1660–1665. [PubMed]
81. Oh SY, Kim JH, Lee KW, et al. Venous thromboembolism in patients with pancreatic adenocarcinoma: Lower incidence in Asian ethnicity. Thromb Res. 2008;122:485–490. [PubMed]
82. Augustin H, Hammerer P, Graefen M, et al. Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: Results of a single center between 1999 and 2002. Eur Urol. 2003;43:113–118. [PubMed]
83. Vaishampayan U, Heilbrun LK, Parchment RE, et al. Phase II trial of fenretinide in advanced renal carcinoma. Invest New Drugs. 2005;23:179–185. [PubMed]
84. Mitchell SY, Lingard EA, Kesteven P, et al. Venous thromboembolism in patients with primary bone or soft-tissue sarcomas. J Bone Joint Surg Am. 2007;89:2433–2439. [PubMed]
85. Athale U, Cox S, Siciliano S, et al. Thromboembolism in children with sarcoma. Pediatr Blood Cancer. 2007;49:171–176. [PubMed]
86. Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: A cohort study and review of the literature. J Clin Oncol. 2000;18:2169–2178. [PubMed]
87. Starling N, Rao S, Cunningham D, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: A report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol. 2009;27:3786–3793. [PubMed]
88. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA. 2008;300:2277–2285. [PubMed]
89. Barbui T, Finazzi G, Grassi A, et al. Thrombosis in cancer patients treated with hematopoietic growth factors: A meta-analysis—On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1996;75:368–371. [PubMed]
90. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational cross-sectional study. Lancet. 2008;371:387–394. [PubMed]
91. Lin J, Wakefield TW, Henke PK. Risk factors associated with venous thromboembolic events in patients with malignancy. Blood Coagul Fibrinolysis. 2006;17:265–270. [PubMed]
92. Eroglu A, Kurtman C, Ulu A, et al. Factor V Leiden and PT G20210A mutations in cancer patients with and without venous thrombosis. J Thromb Haemost. 2005;3:1323–1324. [PubMed]
93. Dentali F, Gianni M, Agnelli G, et al. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: A meta-analysis. J Thromb Haemost. 2008;6:70–75. [PubMed]
94. Rak J, Milsom C, Yu J. Tissue factor in cancer. Curr Opin Hematol. 2008;15:522–528. [PubMed]
95. Kakkar AK, Lemoine NR, Scully MF, et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg. 1995;82:1101–1104. [PubMed]
96. Han LY, Landen CN, Jr, Kamat AA, et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol. 2006;24:755–761. [PubMed]
97. Iversen LH, Thorlacius-Ussing O. Relationship of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost. 2002;87:402–408. [PubMed]
98. ten Wolde M, Kraaijenhagen RA, Prins MH, et al. The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis. Arch Intern Med. 2002;162:1880–1884. [PubMed]
99. Carrier M, Lee AY, Bates SM, et al. Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thromb Res. 2008;123:177–183. [PubMed]
100. Varki A. Trousseau's syndrome: Multiple definitions and multiple mechanisms. Blood. 2007;110:1723–1729. [PubMed]
101. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886–889. [PubMed]
102. Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005;23:4063–4069. [PubMed]
103. Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: A double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 2005;23:4057–4062. [PubMed]
104. Haas S, Kakkar AK, Kemkis-Matthe B, et al. Prevention of venous thromboembolism with low molecular weight heparin in patients with metastatic breast or lung cancer: Results of the TOPIC studies. J Thromb Haemost. 2005;3(suppl 1) abstr OR059.
105. Agnelli G, Gussoni G, Bianchini C, et al. A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: The PROTECHT Study. Presented at Am Soc Hematol Annual Meeting; December 6-9, 2008; San Francisco, CA.
106. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793–800. [PubMed]
107. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–879. [PubMed]
108. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ. 2006;332:325–329. [PMC free article] [PubMed]
109. Kuderer NM, Khorana AA, Francis CW, et al. Venous thromboembolism risk model predicts early progression and overall mortality in cancer patients receiving chemotherapy blood. Blood. 2008;112 abstr 172.

Articles from Journal of Clinical Oncology are provided here courtesy of American Society of Clinical Oncology